HOXA9, ISL1 and ALDH1A3 methylation patterns as prognostic markers for nonmuscle invasive bladder cancer: Array-based DNA methylation and expression profiling

International Journal of Cancer

Volumn 133, Issue 5, 2013, Pages 1135-1142

  Kim, Yong June ^a   Yoon, Hyung Yoon ^a   Kim, Ji Sang ^a   Kang, Ho Won ^a   Min, Byung Dal ^a   Kim, Seon Kyu ^b   Ha, Yun Sok ^a,c   Kim, Isaac Yi ^c   Ryu, Keun Ho ^d   Lee, Sang Cheol ^a   Kim, Wun Jae ^a  

^a Chungbuk National University College of Medicine   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d Chungbuk National University   (South Korea)

Author keywords

gene expression; methylation; microarray analysis; prognosis; urinary bladder neoplasms

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE 1 FAMILY MEMBER A3; ISL LIM HOMEOBOX PROTEIN 1; LIM HOMEODOMAIN PROTEIN; TRANSCRIPTION FACTOR HOXA9; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PYROSEQUENCING; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; SURVIVAL TIME; TUMOR VOLUME;

GENE EXPRESSION; METHYLATION; MICROARRAY ANALYSIS; PROGNOSIS; URINARY BLADDER NEOPLASMS;

ADULT; AGED; ALDEHYDE OXIDOREDUCTASES; DNA METHYLATION; FEMALE; GENE EXPRESSION PROFILING; HOMEODOMAIN PROTEINS; HUMANS; LIM-HOMEODOMAIN PROTEINS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SEQUENCE ANALYSIS, DNA; TRANSCRIPTION FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84879207424     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28121     Document Type: Article

References (34)

1. Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008; 54: 303-14.
2. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007; 178: 2314-30.
3. Cheng L, Zhang S, MacLennan GT, et al. Bladder cancer: translating molecular genetic insights into clinical practice. Hum Pathol 2011; 42: 455-81.
4. Oster B, Thorsen K, Lamy P, et al. Identification and validation of highly frequent CpG island hypermethylation in colorectal adenomas and carcinomas. Int J Cancer 2011; 129: 2855-66.
5. Liu L, Kron KJ, Pethe VV, et al. Association of tissue promoter methylation levels of APC, TGFbeta2, HOXD3 and RASSF1A with prostate cancer progression. Int J Cancer 2011; 129: 2454-62.
6. Ushijima T,. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 2005; 5: 223-31.
7. Kim WJ, Kim YJ,. Epigenetic biomarkers in urothelial bladder cancer. Exp Rev Mol Diagn 2009; 9: 259-69.
8. Baylin SB, Jones PA,. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 2011; 11: 726-34.
9. Kim EJ, Kim YJ, Jeong P, et al. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor. J Urol 2008; 180: 1141-5.
10. Yates DR, Rehman I, Abbod MF, et al. Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res 2007; 13: 2046-53.
11. Catto JW, Azzouzi AR, Rehman I, et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol 2005; 23: 2903-10.
12. Agundez M, Grau L, Palou J, et al. Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guerin response in patients with T1G3 high-risk bladder tumours. Eur Urol 2011; 60: 131-40.
13. Reinert T, Modin C, Castano FM, et al. Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin Cancer Res 2011; 17: 5582-92.
14. Quackenbush J,. Microarray analysis and tumor classification. N Engl J Med 2006; 354: 2463-72.
15. Hoque MO, Kim MS, Ostrow KL, et al. Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res 2008; 68: 2661-70.
16. Kim WJ, Kim EJ, Kim SK, et al. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer 2010; 9: 3.
17. Lee JS, Leem SH, Lee SY, et al. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol 2010; 28: 2660-7.
18. Kim YJ, Yoon HY, Kim SK, et al. EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling. Clin Cancer Res 2011; 17: 4523-30.
19. Kim YJ, Ha YS, Kim SK, et al. Gene signatures for the prediction of response to Bacillus Calmette-Guerin immunotherapy in primary pT1 bladder cancers. Clin Cancer Res 2010; 16: 2131-7.
20. Yoon HY, Kim SK, Kim YW, et al. Combined Hypermethylation of APC and GSTP1 as a Molecular Marker for Prostate Cancer: Quantitative Pyrosequencing Analysis. J Biomol Screen 2012; 17: 987-92.
21. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004; 350: 1828-37.
22. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007; 446: 153-8.
23. Bastian PJ, Ellinger J, Wellmann A, et al. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res 2005; 11: 4097-106.
24. Fernandez AF, Assenov Y, Martin-Subero JI, et al. A DNA methylation fingerprint of 1628 human samples. Genome Res 2012; 22: 407-19.
25. Yamashita S, Tsujino Y, Moriguchi K, et al. Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray. Cancer Sci 2006; 97: 64-71.
26. Ronneberg JA, Fleischer T, Solvang HK, et al. Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer. Mol Oncol 2011; 5: 61-76.
27. Popovic R, Erfurth F, Zeleznik-Le N,. Transcriptional complexity of the HOXA9 locus. Blood Cells Mol Dis 2008; 40: 156-9.
28. Montavon C, Gloss BS, Warton K, et al. Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecol Oncol 2012; 124: 582-8.
29. Son JW, Jeong KJ, Jean WS, et al. Genome-wide combination profiling of DNA copy number and methylation for deciphering biomarkers in non-small cell lung cancer patients. Cancer Lett 2011; 311: 29-37.
30. Ali HR, Dawson SJ, Blows FM, et al. Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance. Breast Cancer Res 2011; 13: R118.
31. Marcato P, Dean CA, Pan D, et al. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells 2011; 29: 32-45.
32. Thaler JP, Koo SJ, Kania A, et al. A postmitotic role for Isl-class LIM homeodomain proteins in the assignment of visceral spinal motor neuron identity. Neuron 2004; 41: 337-50.
33. Karlsson O, Thor S, Norberg T, Ohlsson H, Edlund T,. Insulin gene enhancer binding protein Isl-1 is a member of a novel class of proteins containing both a homeo- and a Cys-His domain. Nature 1990; 344: 879-82.
34. Laugwitz KL, Moretti A, Caron L, et al. Islet1 cardiovascular progenitors: a single source for heart lineages? Development 2008; 135: 193-205.